Accurately determining the location and extent of recurrent prostate cancer lesions with a sensitive imaging modality that allows their early detection may facilitate optimal decision- making for the management of patients with biochemical recurrence (BCR), as indicated by rising prostate-specific antigen (PSA) levels. This evidence concerns the gene KLK3 and prostate carcinoma.